Top Research Papers on Bipolar Disorder

Bipolar disorder has a yearly prevalence of 2%. Other mental and physical conditions occur with bipolar disorder, which is also associated with an increased risk of suicide. Treatment is complex and relies on lithium or intermittent use of antipsychotic drugs.

Evidence is reviewed on the epidemiology, mechanisms, screening, and treatment of bipolar disorders, which shows targeting medical and psychiatric comorbidity, integrating adjunctive psychosocial treatments, and involving caregivers have been shown to improve health outcomes for people with bipolar disorders.

As the understanding of the genetics of BD improves, there is growing optimism that some clear biological pathways will emerge, providing a basis for future studies aimed at molecular diagnosis and novel therapeutics.

Understanding clinical and demographic risk factors for suicide in bipolar disorder remains the best way to prevent suicidal behavior.

Findings related to developmental and perinatal factors as well as epidemiological, clinical, neuropsychological, brain imaging, postmortem brain and genomic studies that provide evidence for a putative neurodevelopmental pathogenesis and etiology of BD are summarized.

This study suggests that outpatients with bipolar disorder may benefit from skills-based psychosocial interventions combined with pharmacotherapy, as suggested in component network meta-analyses.

An overview of the clinical features, diagnostic subtypes, and major treatment modalities available to treat people with bipolar disorder are provided, highlighting recent advances and ongoing therapeutic challenges.

Life expectancy is reduced by approximately 12 to 14 years in people with bipolar disorder, with a 1.6-fold to 2-fold increase in cardiovascular mortality occurring a mean of 17 years earlier compared with the general population.

An updated overview of some of the most prominent pathophysiologic mechanisms in bipolar disorder is presented, from mitochondrial, endoplasmic reticular, and calcium homeostasis, to purinergic, kynurenic, and hormonal/neurotransmitter signaling, showing inflammation to act as a powerful nexus between these systems.

The evidence on efficacy in general, from relapse prevention to acute anti-manic treatment and its role in treating mood episodes with mixed features and bipolar depression and lithium's adverse effects are summarized.

Initial ENIGMA Bipolar Disorder Working Group studies reveal widespread patterns of lower cortical thickness, subcortical volume and disrupted white matter integrity associated with BD, and provide further insights into the pathophysiological mechanisms of BD.

The authors' studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission.

There is a shift in the tryptophan metabolism from serotonin to the kynurenine pathway, across these psychiatric disorders, and a differential pattern exists between mood disorders and SZ, with a preferential metabolism of kynuranine to the potentially neurotoxic quinolinic acid instead of the neuroprotective kynurenic acid in mood disorders but not in SZ.

Mental disorders represent critical public health challenges as they are\nleading contributors to the global burden of disease and intensely influence\nsocial and financial welfare of individuals. The present comprehensive review\nconcentrate on the two mental disorders: Major depressive Disorder (MDD) and\nBipolar Disorder (BD) with noteworthy publications during the last ten years.\nThere is a big need nowadays for phenotypic characterization of psychiatric\ndisorders with biomarkers. Electroencephalography (EEG) signals could offer a\nrich signature for MDD and BD and then they could improv...

This systematic review of the current literature investigating differences in gut microbiota composition in people with the major psychiatric disorders, major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia (SZ), compared to ‘healthy’ controls provides no strong evidence for a difference in the number or distribution of bacteria in those with a mental disorder compared to controls.

The association of bipolar disorder with early and excessive cardiovascular disease was identified over a century ago but the vascular‐bipolar link remains underrecognized, particularly with regard to how this link can contribute to the understanding of pathogenesis and treatment.

It was found that about one in thirteen adults with ADHD was also diagnosed with BD, and nearly one in six adults with BD had ADHD, in a meta-analysis of 71 studies with 646,766 participants from 18 countries.

This paper endeavours to synthesize salient domains in the clinical characterization of the adult patient with bipolar disorder, with the overarching aim to improve health outcomes by informing patient management and treatment considerations.

We report results from the Bipolar Exome (BipEx) collaboration analysis of whole-exome sequencing of 13,933 patients with bipolar disorder (BD) matched with 14,422 controls. We find an excess of ultra-rare protein-truncating variants (PTVs) in patients with BD among genes under strong evolutionary constraint in both major BD subtypes. We find enrichment of ultra-rare PTVs within genes implicated from a recent schizophrenia exome meta-analysis (SCHEMA; 24,248 cases and 97,322 controls) and among binding targets of CHD8. Genes implicated from genome-wide association studies (GWASs) of BD, howeve...

To assess whether bipolar disorder (BD) increases the rate of dementia and whether lithium is related to a lower risk of dementia in BD, a large number of patients with bipolar disorder and a history of lithium use have been diagnosed with BD.

To provide a succinct, clinically useful summary of the management of bipolar disorder, based on the 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (MDcpg2020).

Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders.

Support is provided for the usefulness of lithium against a broad spectrum of clinical issues in Bipolar disorder and its efficacy is comparable to that of more recently developed agents.

Abstract Background Schizophrenia (SCZ) and bipolar disorder (BIP) are debilitating neuropsychiatric disorders, collectively affecting 2% of the world’s population. Recognizing the major impact of these psychiatric disorders on the psychosocial function of more than 200 000 US Veterans, the Department of Veterans Affairs (VA) recently completed genotyping of more than 8000 veterans with SCZ and BIP in the Cooperative Studies Program (CSP) #572. Methods We performed genome-wide association studies (GWAS) in CSP #572 and benchmarked the predictive value of polygenic risk scores (PRS) constructed...

Substantial changes have occurred in the treatment of bipolar disorder over the past 20 years, with second-generation antipsychotics in large measure supplanting traditional mood stabilizers.

Common, modifiable factors may be associated with these sleep-circadian phenotypes and advocate for further development of transdiagnostic interventions that target them.

Bipolar disorder is associated with substantially shortened life expectancy and implementation of multilevel, targeted interventions is urgently needed to reduce this mortality gap.

The present review aims to elucidate pathophysiological mechanisms derived from the MGB axis disruption and possible therapeutic approaches mainly focusing on gut microbiota in the complex network of BD.

Genome-wide association analyses of bipolar disorder cases and controls provide new insights into the etiology of this disorder and identify novel therapeutic leads and potential opportunities for drug repurposing.

Which antipsychotics and/or mood stabilizers are better for patients with bipolar disorder in the maintenance phase is investigated to investigate which antipsychotic combination therapies are better.

Improved clinical management of BD/BD-I and associated comorbidities, together with better medication adherence, may reduce health-care costs and improve patient outcomes.

A comprehensive meta-analysis of whole-brain resting-state functional MRI studies suggests that MDD and BD show a common pattern of aberrant regional intrinsic brain activity which predominantly includes the insula, mPFC, and cerebellum, while the limbic system and occipital cortex may be associated with spatially distinct patterns of brain function.

Bipolar disorder (BD) is a leading cause of worldwide disability among mood disorders. Pathological mechanisms are still vastly unclear, and current treatments with conventional medications are often unsatisfactory in maintaining symptoms control and an adequate quality of life. Consequently, current research is focusing on shedding new light on disease pathogenesis, to improve therapeutic effectiveness. Recent evidence has suggested a prominent role of inflammation in mood disorders. Elevated levels of peripheral proinflammatory mediators have been reported in BD, as well as in other mood dis...

While the ASIR and ASDR due to BPD have been stable, the absolute incidence and DALYs remain high, which represents an increasing burden on health-care systems.

Evidence is reported in support of potential causal associations of several immunological proteins/traits with schizophrenia, and of IL-6 with depression, and from bidirectional MR did not support reverse causality.

IV ketamine was safe, well-tolerated, and effective at improving depressive, anxiety, and functional impairment symptoms in a well-characterized cohort of adults with TRD.

The findings suggest that single-dose IV ketamine/IN esketamine is associated with robust reductions in suicidal thoughts at 2-h, 4-h and 24-h post-intervention.

Evidence is emerging of short-term efficacy of several modern antipsychotics (including cariprazine, lurasidone, olanzapine-fluoxetine, and quetiapine) for bipolar depression, including with mixed features, though they risk adverse metabolic and neurological effects.

On the 75th anniversary of the transistor, the authors engage in a personal and informal celebration of one of the transistor's important progenies, the SiGe HBT, which is 40 years old this month.

To investigate oxidative stress markers and antioxidants in bipolar disorder (BD) and their role in disease progression, data are analyzed through positron emission tomography and X-ray diffraction analysis.